emily o’brien, msph predoctoral trainee february 16, 2010
DESCRIPTION
Emily O’Brien, MSPH Predoctoral Trainee February 16, 2010. Clinical Outcomes among Stroke Patients Receiving t-PA Beyond the Recommended Time Window. The North Carolina Stroke Care Collaborative. Stroke Statistics. - PowerPoint PPT PresentationTRANSCRIPT
Emily O’Brien, MSPH
Predoctoral Trainee
February 16, 2010
The North Carolina Stroke Care Collaborative
Clinical Outcomes among Stroke Patients Receiving t-PA Beyond
the Recommended Time Window
Stroke Statistics 3rd leading cause of death in the U.S. Stroke prevalence is 5,700,000
– Males: 2.3 million– Females: 3.4 million
Per year:– 600,000 new strokes – 180,000 recurrent strokes
Estimated direct and indirect cost of $65.5 billion Effective early management of acute ischemic strokes may lead to better outcomes
Source:Rosamond, W. et al. Heart Disease and Stroke Statistics—2008 Update . A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee . Circulation 117 (4): e25 (2008).
Tissue Plasminogen Activator (t-PA)
FDA-approved treatment for ischemic strokes (1996) Catalyzes conversion of plasminogen to plasmin Associated with
• Increased survival• Reduced disability• Improved neurological outcomes
Hyperfibrinolysis increased risk of hemorrhage Administration within 3 hours used infrequently because of prehospital patient delays
National Institute of Neurological Disorders and Stroke (NINDS) rtPA stroke study: time interaction with favorable neurological outcomes at 3 months
• 0 - 90 minutes: OR= 2.11 (1.33 – 3.55)• 90 - 180 minutes: OR= 1.69 (1.09 – 2.62)
2007: American Heart Association(AHA)/ American Stroke Association(ASA) recommend administration within 3 hours of symptom onset
Time Window for Receipt of t-PA (1996-2007)
Time Window for Receipt of t-PA (2009) Recent European studies examining t-PA given from 3-4.5 hours after symptom onset
1) ECASS-3 Trial: No increased mortality vs. <3 hours 2) SITS-MOST Registry: No differences in mortality,
complications, modified Rankin score May 2009: AHA/ASA recommend administration up to 4.5 hours for patients without contraindications Need for confirmation of results
Source: Del Zoppo, et al. on behalf of the AHA Stroke Council: Expansion of the Time Window for treatment of Acute Ischemic Stroke with Intravenous Tissue Plasminogen Activator: A Science Advisory From the American Heart Association/American Stroke Association. Stroke 2009;40;2945-2948;
Study Aims
1) Estimate the association between use of t-PA beyond 3-hour time interval since symptom onset with
1) Length of hospital stay2) Adverse clinical outcomes
Hemorrhagic complications In-hospital death
One of six Paul Coverdell National Acute Stroke Registries established to measure, track, and improve the quality of stroke care
53 participating hospitals representing 63% of all stroke discharges in NC
N=39073 participants enrolled from January 2005 – January 2010
^^^
^^
^^^^
^^^^ ^^
^̂
^
Legend^ JC-PSC Hospitals
No Hospital CountiesNCSCC Counties
The North Carolina Stroke Care Collaborative (NCSCC)
Study PopulationEnrolled strokes
N=39073 -38045 who did not receive t-PA
-49 transferred orobservation only
-5 with documentedt-PA contraindications
t-PA PatientsN=1028
Patients withoutcontraindications
N=1023
Final Sample Size N= 946
-28 with incomplete mortality or covariate
dataHospitalized
Patients N=974
Exposure Definition
T-PA Timing• “Early t-PA” = receipt <3 hours since time last
known well• “Late t-PA” = receipt >3 hours since time last
known wellOutcome Definitions Length of hospital stay
Discharge date – admission date Adverse clinical outcomes
Complications: Intracerebral hemorrhage or systemic hemorrhage within 36 hoursAND/OR
In-hospital death
Covariates
Gender Age Race (white vs. non-white) Arrival mode (EMS vs. non-
EMS) Prior history of stroke Ambulation status at time of
admission
Statistical Methods Chi-squared test statistics for differences
in proportions Regression analyses
– Multivariable linear regression to estimate adjusted length of stay for early and late t-PA patients
– Multivariable logistic regression to estimate odds ratios (OR) and 95% CIs for the association between time of administration and adverse outcomes
– Robust variance estimators to account for clustering within hospitals
All analyses performed using SAS v. 9.1 (SAS Institute, Cary, NC)
Clinical Characteristics of the Study Population
by Time of Administration (NCSCC: 2005-2008)
Variable.Mean or %
Early t-PA(n=744, 79%)
Late t-PA(n=202, 21%)
p-value
Mean age, years 68.0 66.5 0.22Male (%) 50.8 46.0 0.23Non-white (%) 26.8 26.2 0.89Arrival mode – EMS (%) 86.0 78.2 <0.0
1Mean in-hospital delay, min 78.5 134.2 <0.0
1Mean prehospital delay, min 78.1 112.1 0.46Mean length of stay, days 6.9 6.7 0.43Documented complications (%)
7.3 6.4 0.69
Death prior to discharge (%) 12.4 10.4 0.44
Distribution of time from symptom onset to t-PA among late t-PA patients(NCSCC 2005 – 2010)
Time to T-PA (minutes)
Num
ber o
f pat
ient
s
200 250 300 3500
10
20
30
0
1
2
3
4
5
6
7
8
Leng
th o
f sta
y in
day
s( M
ean;
95%
CI)
Model 1. Crude
Model 2. Age, sex,
race
Model 3. Model 2 + Arrival
mode, ambulation
status
Association between timing of receipt of t-PA and length of stay: NSCCC (2005 – 2010)
Early t-PALate t-PA
Receipt of t-PA > 3 hours after symptom onset* and adverse outcomes†
(NCSCC: 2005 – 2010)
Model Description OR (95% CI)
Model 1. Unadjusted 0.80 (0.52, 1.25)
Model 2. Model 1 + age, race, gender 0.81 (0.52, 1.27)
Model 3. Model 2 + ambulatory status on admission, mode of
arrival
0.82 (0.52, 1.30)
* Early t-PA patients were administered t-PA within 3 hours of the documented last known well time† Adverse oucomes defined as complications including symptomatic intracranial hemorrhage or serious systemic hemorrhage or in-hospital death
Summary Patients receiving t-PA beyond 3 hours
from symptom onset were less likely to arrive by EMS and had longer in-hospital delays
We did not detect differences in length of stay or odds of hemorrhagic complications or death between early and late t-PA patients
Conclusions
Our results are consistent with clinical trials that report no increased risk of complications or mortality at discharge with use of t-PA beyond 3 hours
Future research should examine the association between time of administration, neurological status after discharge, and long-term survival
Acknowledgements Coauthors
Kathryn M RoseMehul D PatelWayne D Rosamond
Staff and participants of the North Carolina Stroke Care Collaborative for their important contributions Support of the NHLBI National Research Award Training Grant
Thank you!
Emily O’BrienUNC Chapel Hill
TABLE 1. Clinical Characteristics of the Study Population. NCSCC (2005-2008)Variables Time-eligible
(n = 744, 79%)Time Ineligible (n = 202, 21%)
Pvalue*
Mean Age (95% CI) 68.0 (66.9, 69.1) 66.5 (64.4, 68.6)Gender
Male 378 (50.8) 93 (46.0) 0.23Female 366 (49.3) 109 (54.0)
RaceWhite 545 (73.3) 149 (73.8) 0.89
Non-White 199 (26.8) 53 (26.2)Arrival Mode
EMS 640 (86.0) 158 (78.2) 0.007Non-EMS 104 (14.0) 44 (21.8)
Health InsurancePrivate 437 (58.7) 118 (58.4) 0.93
Public/None 307 (41.3) 84 (41.6)Time to administration
(min)134.7 (132.4, 137.6)
250.1 (224.3, 276.0)
Length of stay, Days (95% CI)
6.9 (6.4, 7.4) 6.7 (5.8, 7.6)
Documented complicationsYes 54 (7.3) 13 (6.4) 0.69No 690 (92.7) 189 (93.6)
Expired on dischargeYes 92 (12.4) 21 (10.4) 0.44No 652 (87.6) 181 (89.6)
*Chi-squared analysis for differences in proportions
Figure. SICH and mortality in observational studies and randomised trials with alteplase in ischaemic strokeFigure shows mean and 95% CI. NR=not reported. *Median age except in STARS (mean). †Patients who did not meet inclusion/exclusion criteria were systematically excluded. ‡SICH according to NINDS definition: NIHSS ≥1 and any haemorrhage on CT at 24–36h.2 §3-month mortality except for STARS (1 month).
Alteplase and mortality in observational studies and RCTs
Receipt of t-PA 3 – 4.5 hours after symptom onset* and adverse outcomes†
(NCSCC: 2005 – 2010)
Model Description OR (95% CI)
Model 1. Unadjusted 0.82 (0.52, 1.30)
Model 2. Model 1 + age, race, gender 0.82 (0.52, 1.31)
Model 3. Model 2 + ambulatory status on admission, mode of
arrival
0.81 (0.51, 1.31)
* Early t-PA patients were administered t-PA within 3 hours of the documented last known well time† Adverse oucomes defined as complications including symptomatic intracranial hemorrhage or serious systemic hemorrhage or in-hospital death
Distribution of time from symptom onset to t-PA (NCSCC 2005 – 2010)
0 50 100 150 200 250 300 3500
20
40
60
80
100
120
Time to T-PA (minutes)
Num
ber o
f pat
ient
s
1
10
Early tPA
Late tPA
Model 1. Crude
Model 2. Age, sex,
race
Model 3. Model 2 + Arrival mode,
ambulation status
Mea
n da
ys( l
og tr
ansf
orm
ed; 9
5% C
I)
Association between timing of receipt of t-PA and length of stay: NSCCC (2005 – 2010).
Distribution of time from symptom onset to t-PA among early t-PA patients(NCSCC 2005 – 2010)
Time to T-PA (minutes)
Num
ber o
f pat
ient
s
0 50 100 150 2000
50
100
150